The estimated Net Worth of Bruno Jean Marie Baillavoine is at least $824 Mille dollars as of 6 July 2021. Mr. Baillavoine owns over 1,250 units of Cel-Sci stock worth over $7,048 and over the last 9 years he sold CVM stock worth over $0. In addition, he makes $816,852 as Independent Director at Cel-Sci.
Sign up
Mr. Baillavoine CVM stock SEC Form 4 insiders trading
Bruno has made over 3 trades of the Cel-Sci stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 1,250 units of CVM stock worth $10,000 on 6 July 2021.
The largest trade he's ever made was buying 1,250 units of Cel-Sci stock on 6 July 2021 worth over $10,000. On average, Bruno trades about 229 units every 38 days since 2015. As of 6 July 2021 he still owns at least 5,973 units of Cel-Sci stock.
You can see the complete history of Mr. Baillavoine stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Bruno Baillavoine biography
Bruno Jean-Marie Baillavoine serves as Independent Director of the Company. Mr. Baillavoine has been the Director, Head of Pericles Group UK the subsidiary of the Paris based leading French consulting firm, Pericles Consulting Holdings SAS. Pericles is an expert in the fields of Banking, Finance, Asset Management and Insurance with over 350 institutional clients. He has also been an advisor to the board of CSL Inc., Combatives Sports League, a US Mix Martial Arts company since 2017 and was appointed to the Board in 2019. Between 2010-2016, Mr. Baillavoine was a partner of Globomass Holdings Limited, a London, England based developer of renewable energy projects from concept through final operations. From 2012-2016 Mr. Baillavoine was the Executive Chairman of Globomass Holdings. Globomass was acquired by CleanBay Inc. in 2016.Mr. Baillavoine remains a significant shareholder in CleanBay Inc. Between 1978 and 1982 he was the marketing manager of Ravenhead Ltd., a manufacturer of glass tableware, and part of United Distillers Group (later acquired by Grand Metropolitan). During this time Mr. Baillavoine became the UK Business Manager where he restored market share and profit for United Distillers. From 1982 to 1986 Mr. Baillavoine was Group Corporate Planning and Group Marketing Director for Prontaprint where he expanded the number of shops to 500 locations in four years. Mr. Baillavoine joined Grand Metropolitan Plc between 1986-1988 (now Diageo Plc), an FTSE 100 beverage, food, hotel and leisure company, as director in the Special Operations division. In this capacity, he developed plans for Grand Met’s trouble-shooting division for over 20,000 Grand Met retail outlets. From 1988-1991 he was the Managing Director of Nutri Systems (UK) Ltd., a subsidiary of the US based provider of professionally supervised weight loss programs. Between 1991 and 1995,
What is the salary of Bruno Baillavoine?
As the Independent Director of Cel-Sci, the total compensation of Bruno Baillavoine at Cel-Sci is $816,852. There are 6 executives at Cel-Sci getting paid more, with Geert Kersten having the highest compensation of $4,546,360.
How old is Bruno Baillavoine?
Bruno Baillavoine is 66, he's been the Independent Director of Cel-Sci since 2015. There are 7 older and 6 younger executives at Cel-Sci. The oldest executive at Cel-Sci Corp. is Dr. Daniel H. Zimmerman Ph.D., 80, who is the Sr. VP of Research & Cellular Immunology.
What's Bruno Baillavoine's mailing address?
Bruno's mailing address filed with the SEC is 8229 BOONE BLVD., SUITE 802, VIENNA, VA, 22182.
Insiders trading at Cel-Sci
Over the last 21 years, insiders at Cel-Sci have traded over $3,069,559 worth of Cel-Sci stock and bought 1,693,350 units worth $1,328,136 . The most active insiders traders include Clara Maximilian De, Geert R Kersten e Eyal Talor. On average, Cel-Sci executives and independent directors trade stock every 50 days with the average trade being worth of $42,938. The most recent stock trade was executed by Robert Eugene Watson on 8 May 2024, trading 20,000 units of CVM stock currently worth $27,800.
What does Cel-Sci do?
cel-sci corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. the company's lead investigational immunotherapy is multikine, which is under phase iii clinical trial for the treatment of head and neck cancer. its ligand epitope antigen presentation system (leaps), a pre-clinical patented t-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. the company also develops leaps-h1n1-dc; cel-2000 and cel-4000 are product candidates for the treatment of rheumatoid arthritis; and leaps cov-19, a product candidate to treat covid-19 coronavirus. cel-sci corporation has a collaboration agreement with the university of georgia's center for vaccines and immunology to develop leaps covid-19 immunotherapy. the company was founded in 1983 and is headquartered in vienna, virginia.
What does Cel-Sci's logo look like?
Complete history of Mr. Baillavoine stock trades at Cel-Sci
Cel-Sci executives and stock owners
Cel-Sci executives and other stock owners filed with the SEC include:
-
Geert Kersten,
Chief Executive Officer, Treasurer, Director -
Patricia Prichep,
Senior Vice President - Operations, Corporate Secretary -
Eyal Talor,
Chief Scientific Officer -
Daniel Zimmerman,
Senior Vice President - Research, Cellular Immunology -
John Cipriano,
Senior Vice President - Regulatory Affairs -
Peter Young,
Independent Director -
Robert Watson,
Independent Director -
Bruno Baillavoine,
Independent Director -
Geert R. Kersten,
CEO, Principal Accounting & Financial Officer, Treasurer and Director -
Geert R. Kersten Esq.,
Chief Exec. & Financial Officer, Treasurer and Director -
Dr. Eyal Talor Ph.D.,
Chief Scientific Officer -
Patricia B. Prichep,
Sr. VP of Operations & Corp. Sec. -
Dr. Daniel H. Zimmerman Ph.D.,
Sr. VP of Research & Cellular Immunology -
John Cipriano,
Sr. VP of Regulatory Affairs -
Clara Maximilian De,
President -
Alexander G Esterhazy,
Director -
C Richard Kinsolving,
Director -
Gail K Naughton,
Director